BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
1432 results:

  • 1. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
    Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
    Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
    J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epidemiological and clinicopathological features of KRAS, NRAS, braf mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
    Cheng XF; Zhao F; Chen D; Liu FL
    World J Gastroenterol; 2024 Feb; 30(7):663-672. PubMed ID: 38515943
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/braf wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
    Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Evolving survival gains in patients with young-onset colorectal cancer and synchronous resectable liver metastases.
    Maki H; Haddad A; Lendoire M; Newhook TE; Peacock O; Bednarski BK; Konishi T; Vauthey JN; You YN
    Eur J Surg Oncol; 2024 Apr; 50(4):108057. PubMed ID: 38461567
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Fully semantic segmentation for rectal cancer based on post-nCRT MRl modality and deep learning framework.
    Xia S; Li Q; Zhu HT; Zhang XY; Shi YJ; Yang D; Wu J; Guan Z; Lu Q; Li XT; Sun YS
    BMC Cancer; 2024 Mar; 24(1):315. PubMed ID: 38454349
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Concurrent NRAS-braf variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. BCL-X
    Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
    Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Mucin phenotype and genetic alterations in non-V600E braf-mutated colorectal cancer.
    Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
    Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
    Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
    Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Association of RNF43 Genetic Alterations With braf
    Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
    JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical features and mutation analysis of class 1/2/3 braf mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
    Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
    J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
    Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 72.